European Child & Adolescent Psychiatry

, Volume 16, Issue 5, pp 347–351 | Cite as

Is OPTAx™ useful for monitoring the effect of stimulants on hyperactivity and inattention?

A brief report
  • Janne Tabori-Kraft
  • Merete Juul Sørensen
  • Martin Kærgaard
  • Søren Dalsgaard
  • Per Hove Thomsen



The purpose of this study was to investigate whether OPTAx, an objective measurement of hyperactivity, impulsivity and inattention can be used to measure the positive clinical effect of stimulants found in children with hyperkinetic disorder (HKD) or attention deficit disorder without hyperactivity.


A total of 22 boys and one girl, with ages ranging between 7–12 years, diagnosed with HKD or attention deficit disorder without hyperactivity and receiving treatment with stimulants were tested with OPTAx, with and without stimulants. The main parameters investigated were: displacement, area, accuracy, variability, errors of commission and errors of omission.


OPTAx showed a significant improvement on all parameters during stimulant treatment compared with no treatment. The improvement measured by OPTAx was supported by clinical assessment, which found that 95% of the children improved much or very much on the Clinical Global Assessment Scale during stimulant treatment.


The objective parameters of the OPTAx reflected the clinical improvement found in children with HKD or attention deficit disorder without hyperactivity during stimulant treatment. This suggests a greater role for objective measurements such as OPTAx in daily clinical practise.


inattention stimulants OPTAx 


  1. 1.
    Washington D (1994) American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. (DSM-IV)Google Scholar
  2. 2.
    World Health Organization Geneva (1993) The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic criteria for research. World health organization, GenevaGoogle Scholar
  3. 3.
    Faraone SV, Doyle AE (2001) The nature and heritability of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 10:299–2ixPubMedGoogle Scholar
  4. 4.
    Carlson CL, Tamm L, Gaub M (1997) Gender differences in children with ADHD, ODD, and co-occurring ADHD/ODD identified in a school population. J Am Acad Child Adolesc Psychiatry 36:1706–1714PubMedCrossRefGoogle Scholar
  5. 5.
    Graetz BW, Sawyer MG, Baghurst P (2005) Gender differences among children with DSM-IV ADHD in Australia. J Am Acad Child Adolesc Psychiatry 44:159–168PubMedCrossRefGoogle Scholar
  6. 6.
    Biederman J, Mick E, Faraone SV, Braaten E, Doyle A, Spencer T, Wilens TE, Frazier E, Johnson MA (2002) Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 159:36–42PubMedCrossRefGoogle Scholar
  7. 7.
    Biederman J, Monuteaux MC, Doyle AE, Seidman LJ, Wilens TE, Ferrero F, Morgan CL, Faraone SV (2004) Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol 72:757–766PubMedCrossRefGoogle Scholar
  8. 8.
    Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH (2002) Conduct problems, gender and adult psychiatric outcome of children with attention-deficit hyperactivity disorder. Br J Psychiatry 181:416–421PubMedCrossRefGoogle Scholar
  9. 9.
    Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R (1999) The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and meta-analyses. Can J Psychiatry 44:1025–1035PubMedGoogle Scholar
  10. 10.
    Rapoport JL, Buchsbaum MS, Zahn TP, Weingartner H, Ludlow C, Mikkelsen EJ (1978) Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 199:560–563PubMedCrossRefGoogle Scholar
  11. 11.
    Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F (2000) Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283:1025–1030PubMedCrossRefGoogle Scholar
  12. 12.
    Marwick C (2003) US doctor warns of misuse of prescribed stimulants. BMJ 326:67–68CrossRefGoogle Scholar
  13. 13.
    Eaves L, Rutter M, Silberg JL, Shillady L, Maes H, Pickles A (2000) Genetic and environmental causes of covariation in interview assessments of disruptive behavior in child and adolescent twins. Behav Genet 30:321–334PubMedCrossRefGoogle Scholar
  14. 14.
    Greenberg LM (1987) An objective measure of methylphenidate response: clinical use of the MCA. Psychopharmacol Bull 23:279–282PubMedGoogle Scholar
  15. 15.
    Teicher MH, Anderson CM, Polcari A, Glod CA, Maas LC, Renshaw PF (2000) Functional deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nat Med 6:470–473PubMedCrossRefGoogle Scholar
  16. 16.
    Teicher MH, Lowen SB, Polcari A, Foley M, McGreenery CE (2004) Novel strategy for the analysis of CPT data provides new insight into the effects of methylphenidate on attentional states in children with ADHD. J Child Adolesc Psychopharmacol 14:219–232PubMedCrossRefGoogle Scholar
  17. 17.
    Teicher MH, Ito Y, Glod CA, Barber NI (1996) Objective measurement of hyperactivity and attentional problems in ADHD. J Am Acad Child Adolesc Psychiatry 35:334–342PubMedCrossRefGoogle Scholar
  18. 18.
    Barkley RA (1991) The ecological validity of laboratory and analogue assessment methods of ADHD symptoms. J Abnorm Child Psychol 19:149–178PubMedCrossRefGoogle Scholar
  19. 19.
    Heiser P, Frey J, Smidt J, Sommerlad C, Wehmeier PM, Hebebrand J, Remschmidt H (2004) Objective measurement of hyperactivity, impulsivity, and inattention in children with hyperkinetic disorders before and after treatment with methylphenidate. Eur Child Adolesc Psychiatry 13:100–104PubMedCrossRefGoogle Scholar
  20. 20.
    Losier BJ, McGrath PJ, Klein RM (1996) Error patterns on the continuous performance test in non-medicated and medicated samples of children with and without ADHD: a meta-analytic review. J Child Psychol Psychiatry 37:971–987PubMedCrossRefGoogle Scholar
  21. 21.
    Matier K, Halperin JM, Sharma V, Newcorn JH, Sathaye N (1992) Methylphenidate response in aggressive and non-aggressive ADHD children: distinctions on laboratory measures of symptoms. J Am Acad Child Adolesc Psychiatry 31:219–225PubMedCrossRefGoogle Scholar
  22. 22.
    Guy W (2005) ECDEU Assessment Manual for Psychopharmacology—Revised (DHEW Publ No ADM 76–338). Rockville, MD. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976, pp 218–222Google Scholar
  23. 23.
    StataCorp. 2003. Stata Statistical Software: Release 8.0. 2005. College Station, TX: Stata Corporation. Ref Type: Computer ProgramGoogle Scholar

Copyright information

© Steinkopff Verlag 2007

Authors and Affiliations

  • Janne Tabori-Kraft
    • 1
  • Merete Juul Sørensen
    • 1
  • Martin Kærgaard
    • 1
  • Søren Dalsgaard
    • 1
  • Per Hove Thomsen
    • 1
  1. 1.Psychiatric Hospital for Children and Adolescents, Aarhus University HospitalRisskovDenmark

Personalised recommendations